IBM Watson Health and Illumina, Inc. announced partnership to expand access to genome data interpretation by integrating Watson for Genomics into Illumina's BaseSpace® Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation. By adding Watson for Genomics to Illumina's next-generation sequencing platform, researchers who use Illumina's cancer genome sequencing panel will have rapid access to information to help interpret the broad array of variant data produced by TruSight Tumor 170. Illumina's TruSight® Tumor 170 is a solid tumor profiling panel designed to detect a comprehensive set of variants across 170 genes.